vs
Side-by-side financial comparison of Cushman & Wakefield Ltd. (CWK) and HAEMONETICS CORP (HAE). Click either name above to swap in a different company.
Cushman & Wakefield Ltd. is the larger business by last-quarter revenue ($2.5B vs $346.4M, roughly 7.3× HAEMONETICS CORP). On growth, Cushman & Wakefield Ltd. posted the faster year-over-year revenue change (11.0% vs 4.8%). HAEMONETICS CORP produced more free cash flow last quarter ($209.9M vs $-255.7M). Over the past eight quarters, Cushman & Wakefield Ltd.'s revenue compounded faster (5.3% CAGR vs 1.5%).
Cushman & Wakefield Inc. is an American global commercial real estate and property management services firm. The company's corporate headquarters is located in Chicago, Illinois. It is named after co-founders J. Clydesdale Cushman and Bernard Wakefield.
Haemonetics Corporation is a global provider of blood and plasma supplies and services. The company was founded in Natick, Massachusetts by Dr. Allen (Jack) Latham in the 1970s.
CWK vs HAE — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2026
| Metric | | |
|---|---|---|
| Revenue | $2.5B | $346.4M |
| Net Profit | — | $97.3M |
| Gross Margin | — | 57.2% |
| Operating Margin | 2.3% | 36.1% |
| Net Margin | — | 28.1% |
| Revenue YoY | 11.0% | 4.8% |
| Net Profit YoY | — | — |
| EPS (diluted) | $-0.05 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $2.5B | $346.4M | ||
| Q4 25 | $2.9B | $339.0M | ||
| Q3 25 | $2.6B | $327.3M | ||
| Q2 25 | $2.5B | $321.4M | ||
| Q1 25 | $2.3B | $330.6M | ||
| Q4 24 | $2.6B | $348.5M | ||
| Q3 24 | $2.3B | $345.5M | ||
| Q2 24 | $2.3B | $336.2M |
| Q1 26 | — | $97.3M | ||
| Q4 25 | $-22.4M | $44.7M | ||
| Q3 25 | $51.4M | $38.7M | ||
| Q2 25 | $57.3M | $34.0M | ||
| Q1 25 | $1.9M | $58.0M | ||
| Q4 24 | $112.9M | $37.5M | ||
| Q3 24 | $33.7M | $33.8M | ||
| Q2 24 | $13.5M | $38.4M |
| Q1 26 | — | 57.2% | ||
| Q4 25 | — | 59.7% | ||
| Q3 25 | — | 59.5% | ||
| Q2 25 | — | 59.8% | ||
| Q1 25 | — | 58.4% | ||
| Q4 24 | — | 55.5% | ||
| Q3 24 | — | 54.2% | ||
| Q2 24 | — | 52.0% |
| Q1 26 | 2.3% | 36.1% | ||
| Q4 25 | 6.1% | 19.9% | ||
| Q3 25 | 4.1% | 17.9% | ||
| Q2 25 | 4.9% | 16.8% | ||
| Q1 25 | 2.0% | 21.6% | ||
| Q4 24 | 6.6% | 16.9% | ||
| Q3 24 | 3.2% | 15.0% | ||
| Q2 24 | 3.1% | 11.8% |
| Q1 26 | — | 28.1% | ||
| Q4 25 | -0.8% | 13.2% | ||
| Q3 25 | 2.0% | 11.8% | ||
| Q2 25 | 2.3% | 10.6% | ||
| Q1 25 | 0.1% | 17.5% | ||
| Q4 24 | 4.3% | 10.8% | ||
| Q3 24 | 1.4% | 9.8% | ||
| Q2 24 | 0.6% | 11.4% |
| Q1 26 | $-0.05 | — | ||
| Q4 25 | $-0.10 | $0.95 | ||
| Q3 25 | $0.22 | $0.81 | ||
| Q2 25 | $0.25 | $0.70 | ||
| Q1 25 | $0.01 | $1.17 | ||
| Q4 24 | $0.49 | $0.74 | ||
| Q3 24 | $0.14 | $0.66 | ||
| Q2 24 | $0.06 | $0.74 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $600.6M | $245.4M |
| Total DebtLower is stronger | — | $1.2B |
| Stockholders' EquityBook value | $2.0B | $796.3M |
| Total Assets | $7.6B | $2.4B |
| Debt / EquityLower = less leverage | — | 1.53× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $600.6M | $245.4M | ||
| Q4 25 | $784.2M | $363.4M | ||
| Q3 25 | $634.4M | $296.4M | ||
| Q2 25 | $618.2M | $292.9M | ||
| Q1 25 | $623.2M | $306.8M | ||
| Q4 24 | $793.3M | $320.8M | ||
| Q3 24 | $775.4M | $299.3M | ||
| Q2 24 | $567.3M | $344.4M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $2.7B | $1.2B | ||
| Q3 25 | $2.8B | $1.2B | ||
| Q2 25 | $3.0B | $1.2B | ||
| Q1 25 | $3.0B | $1.2B | ||
| Q4 24 | $3.0B | — | ||
| Q3 24 | $3.1B | — | ||
| Q2 24 | $3.1B | — |
| Q1 26 | $2.0B | $796.3M | ||
| Q4 25 | $2.0B | $911.5M | ||
| Q3 25 | $2.0B | $849.2M | ||
| Q2 25 | $1.9B | $882.3M | ||
| Q1 25 | $1.8B | $820.8M | ||
| Q4 24 | $1.8B | $906.9M | ||
| Q3 24 | $1.7B | $878.9M | ||
| Q2 24 | $1.6B | $905.4M |
| Q1 26 | $7.6B | $2.4B | ||
| Q4 25 | $7.7B | $2.5B | ||
| Q3 25 | $7.7B | $2.4B | ||
| Q2 25 | $7.6B | $2.5B | ||
| Q1 25 | $7.4B | $2.5B | ||
| Q4 24 | $7.5B | $2.5B | ||
| Q3 24 | $7.5B | $2.5B | ||
| Q2 24 | $7.3B | $2.5B |
| Q1 26 | — | 1.53× | ||
| Q4 25 | 1.40× | 1.34× | ||
| Q3 25 | 1.45× | 1.44× | ||
| Q2 25 | 1.57× | 1.39× | ||
| Q1 25 | 1.70× | 1.49× | ||
| Q4 24 | 1.73× | — | ||
| Q3 24 | 1.81× | — | ||
| Q2 24 | 1.91× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-243.5M | $293.2M |
| Free Cash FlowOCF − Capex | $-255.7M | $209.9M |
| FCF MarginFCF / Revenue | -10.1% | 60.6% |
| Capex IntensityCapex / Revenue | — | 9.5% |
| Cash ConversionOCF / Net Profit | — | 3.01× |
| TTM Free Cash FlowTrailing 4 quarters | $203.9M | $417.1M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $-243.5M | $293.2M | ||
| Q4 25 | $257.3M | $93.6M | ||
| Q3 25 | $235.5M | $111.3M | ||
| Q2 25 | $9.6M | $17.4M | ||
| Q1 25 | $-162.0M | $116.6M | ||
| Q4 24 | $115.2M | $43.8M | ||
| Q3 24 | $196.1M | $48.8M | ||
| Q2 24 | $21.8M | $-27.4M |
| Q1 26 | $-255.7M | $209.9M | ||
| Q4 25 | $234.3M | $87.2M | ||
| Q3 25 | $225.0M | $106.3M | ||
| Q2 25 | $300.0K | $13.6M | ||
| Q1 25 | $-166.6M | $100.9M | ||
| Q4 24 | $105.9M | $35.2M | ||
| Q3 24 | $186.7M | $39.4M | ||
| Q2 24 | $10.0M | $-33.1M |
| Q1 26 | -10.1% | 60.6% | ||
| Q4 25 | 8.0% | 25.7% | ||
| Q3 25 | 8.6% | 32.5% | ||
| Q2 25 | 0.0% | 4.2% | ||
| Q1 25 | -7.3% | 30.5% | ||
| Q4 24 | 4.0% | 10.1% | ||
| Q3 24 | 8.0% | 11.4% | ||
| Q2 24 | 0.4% | -9.8% |
| Q1 26 | — | 9.5% | ||
| Q4 25 | 0.8% | 1.9% | ||
| Q3 25 | 0.4% | 1.5% | ||
| Q2 25 | 0.4% | 1.2% | ||
| Q1 25 | 0.2% | 4.7% | ||
| Q4 24 | 0.4% | 2.5% | ||
| Q3 24 | 0.4% | 2.7% | ||
| Q2 24 | 0.5% | 1.7% |
| Q1 26 | — | 3.01× | ||
| Q4 25 | — | 2.09× | ||
| Q3 25 | 4.58× | 2.88× | ||
| Q2 25 | 0.17× | 0.51× | ||
| Q1 25 | -85.26× | 2.01× | ||
| Q4 24 | 1.02× | 1.17× | ||
| Q3 24 | 5.82× | 1.44× | ||
| Q2 24 | 1.61× | -0.71× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CWK
| Services | $1.7B | 69% |
| Leasing | $497.7M | 20% |
| Capital markets | $181.6M | 7% |
| Valuation and other | $113.8M | 4% |
HAE
| Hospital | $159.6M | 46% |
| Plasma | $130.3M | 38% |
| Blood Center | $56.4M | 16% |
